Trial
NCT05999968
Abemaciclib Plus Darolutamide in Prostate Cancer That Has Spread After Initial Treatment
Phase ITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
Eli Lilly and Company
Collaborators
Bayer
Condition
Prostatic Neoplasms
Intervention
Abemaciclib
Why stopped
The study was terminated early as related study I3Y-MC-JPCM (NCT03706365) did not meet its primary endpoint.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-06-26